RENE Reneuron Group Plc

TIDMRENE

RNS Number : 7497S

ReNeuron Group plc

18 November 2021

ReNeuron Group plc

("ReNeuron" or the "Company")

Notice of Results

Investor presentation

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its interim results for the six months ended 30 September 2021 and business update on Tuesday 30 November 2021.

Analyst briefing

Olav Hellebø, Chief Executive Officer, Catherine Isted, Chief Financial Officer and Dr Stefano Pluchino, Chief Scientific Officer will be hosting a briefing for analysts which will take place in the City of London on Tuesday 30 November 2021 at 13.00 (GMT) / 08:00 EST. A live webcast of the presentation will also be available for those unable to attend the meeting in-person.

For more information and to register to attend the meeting in-person or require the link to the live webcast, please email reneuron@walbrookpr.com or call +44 (0)20 7933 8785.

Investor Briefing

Management will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 15.00 (GMT) on Tuesday 30 November. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here : https://www.investormeetcompany.com/reneuron-group-plc/register-investor

Investors who already follow ReNeuron on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

ENDS

Contacts:

 
 ReNeuron                                                         www.reneuron.com/investors 
 Olav Hellebø, Chief Executive                                          Via Walbrook PR 
  Officer 
  Catherine Isted, Chief Financial Officer 
 
 Stifel Nicolaus Europe Limited (NOMAD 
  and Joint Broker) 
  Ben Maddison, Stewart Wallace                                          +44 (0)20 7710 7600 
 
 Allenby Capital Limited (Joint Broker)                                  +44 (0)20 3328 5656 
 James Reeve/George Payne (Corporate 
  Finance) 
 Stefano Aquilino (Sales & Corporate 
  Broking) 
 
 Walbrook PR (Media & Investor Relations)     +44 (0)20 7933 8780 or reneuron@walbrookpr.com 
                                                           +44 (0)7980 541 893 / +44 (0)7407 
 Paul McManus, Alice Woodings                                                        804 654 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORKDLFFFFLZFBL

(END) Dow Jones Newswires

November 18, 2021 02:00 ET (07:00 GMT)

Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024